Singapore: Health Sciences Authority launches public consultation on the proposed exemption from manufacturer's licensing and product registration requirements for artificial intelligence - software as a medical device

In brief

On 19 May 2025, the Health Sciences Authority (HSA) launched its public consultation on the proposed exemption from manufacturer's licensing and product registration requirements for artificial intelligence software as a medical device (AI-SaMDs) under the Health Products Act 2007 ("Act").

The amendments propose expanding the exemptions presently set out in the Health Products (Medical Devices) Regulations 2010 ("Regulations") to include AI-SaMDs developed by selected public healthcare entities for use in public healthcare. Alongside these exemptions, the HSA is also looking to add additional safeguards and controls for the exempted AI-SaMDs.

The consultation period runs from 19 May 2025 to 19 June 2025.


Contents

Key takeaways

The Singapore regulatory landscape has been evolving rapidly in relation to digital health and AI in healthcare issues. The government has been pushing for the increased adoption of such capabilities into its healthcare ecosystem to augment the delivery of healthcare services.

Companies involved in the manufacture and distribution of such digital health systems and/or services, especially AI-SaMDs, should stay aware of the latest developments to ensure that they are aligned with all regulatory requirements and recommended best practices.

In more detail

Currently, specified healthcare service licensees that develop an AI-SaMD for in-house use (i.e., for their own patients) are exempted from requirements for a manufacturer's license and product registration. This exemption is designed to minimize the regulatory burden on the licensees, so that patients' clinical needs can be addressed more efficiently. The exempted licensees are still subject to existing clinical governance frameworks, safety protocols and oversight in the use of the AI-SaMDs.

Under the proposed amendments, the MOH Office for Healthcare Transformation (MOHT), Synapxe and public healthcare clusters and institutions will be included as exempted healthcare service licensees. These entities play a key role in scaling the use of AI across multiple institutions by leveraging technology to develop AI-SaMDs customized for public healthcare institutions. The proposed exemptions aim to create a regulatory sandbox for deploying AI-SaMDs developed by and for public healthcare institutions. This sandbox will serve as a testing ground to assess the effectiveness and impact of AI in public healthcare.

Proposed exemption under the Act

The proposed exemption will expand the current exception to include AI-SaMDs that meet the following requirements:

  1. Developed by MOHT, Synapxe and public healthcare clusters and institutions
  2. Classified as class A (low risk) or class B (moderately low risk) under the Third Schedule of the Regulations
  3. Developed under the supervision and oversight of a clinician employed in a public healthcare institution holding the position of consultant or higher
  4. Only for in-house use by public healthcare licensees
  5. Notified to the HSA at the point of deployment

Proposed additional safeguards and controls

The HSA has proposed the following safeguards and controls for MOHT, Synapxe and public healthcare clusters and institutions that develop the AI-SaMDs:

  1. Self-attest annually to a quality management system (ISO 13485), and check against an internal product control checklist.
  2. Continue to adhere to internal governance controls for public healthcare institutions, including cyber and data security requirements.
  3. Ensure that the AI-SaMD is endorsed by the chair of the medical board or the chief executive officer of the public healthcare licensee before use.
  4. Report any adverse effect to the HSA.

Post-market controls, including adverse effect reporting requirements, will continue to apply, where breaches may be liable to fines of up to SGD 20,000 (approximately USD 15,000) and/or imprisonment for up to 12 months.

The HSA will monitor the proposed exemption for 12 months to evaluate the regulatory sandbox. If there are not enough indicators or AI-SaMDs developed during this period, the duration may be extended for a more robust assessment.

* * * * *

LOGO_Wong&Leow_Singapore

© 2025 Baker & McKenzie. Wong & Leow. All rights reserved. Baker & McKenzie. Wong & Leow is incorporated with limited liability and is a member firm of Baker & McKenzie International, a global law firm with member law firms around the world. In accordance with the common terminology used in professional service organizations, reference to a "principal" means a person who is a partner, or equivalent, in such a law firm. Similarly, reference to an "office" means an office of any such law firm. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.

Contact Information

Copyright © 2025 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.